Dental extractions in patients on oral or intravenous bisphosphonate therapy: A clinical dilemma
Abstract
Dental extraction has been touted to be a potential trigger for the onset of bisphosphonate-related osteonecrosis of the jaw (BRONJ). In this article, we carry out a comprehensive discussion on the pharmacology of bisphosphonates. This article also aims to assess and outline the pathogenesis of BRONJ, the outcome of dental extractions on patients receiving bisphosphonate therapy and to draw a protocol for its prevention and management.
Downloads
References
Sambrook P, Cooper C. Osteoporosis. Lancet. 2006;367:2010-2018.
Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17:1726–1733.
Ruggiero, SL. Guidelines for the diagnosis of bisphosphonate-related osteonecrosis of the jaw (BRONJ). Clin Cases Miner Bone Metab. 2007;4:37-42.
McLeod NM, Brennan PA, Ruggiero SL. Bisphosphonate osteonecrosis of the jaw: a historical and contemporary review. Surgeon. 2012;10:36-42.
Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci. 2007;1117:209-257.
Russell RG, Watts NB, Ebetino FH, Rogetrs MJ. Mechanisms of action of Bisphosphonates: Similarities and differences and their potential influence on clinical efficiency. Osteoporosis Int 2008;19:733-59.
Martin TJ, Grin V: Bisphosphonates – mechanisms of action, Aust Prescriber 23:130-132, 2000.
Chun YH, Foster BL, Lukasavage PA: Bisphosphonate modulates cementoblast behaviour in vitro, J Periodontol 76:1890-1900, 2005
Kearns G, Sharma A, Perrott D et al: Placement of endosseous implants in children and adolescents with hereditary ectodermal dysplasia, Oral Surg Oral Med Oral Pathol Oral Radiol Endod 88:5-10, 1999.
Bergendal B, Bergendal T, Hallonsten AL et al: A multidisciplinary approach to oral rehabilitation with osseointegrated implants in children and adolescents with multiple aplasia, Eur J Orthod 18:119-129, 1996.
Brotons A, Penarrocha M. Orofacial neurogenic pain and maxillofacial ischemic osteonecrosis. A review. Med Oral. 2003;8(3):157–65.
Marx RE. Osteoradionecrosis: a new concept of its pathophysiology. J Oral Maxillofac Surg. 1983;41(5):283–8.
Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115–7.
Ruggeiro SL. Emerging Concepts in the Management and Treatment of Osteonecrosis of the Jaw. Oral Maxillofacial Surg Clin N Am 25 (2013) 11–20
Wood J, Bonjean K, Ruetz S. Novel antiangiogenic effects of the bisphosphonate compound zolendronic acid. J Pharmacol Exp Ther 2002;302:1055–61.
Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002;62:6538–44.
Deckers M, Van Beek E, Van Der Pluijm G, et al. Dissociation of angiogenesis and osteoclastogenesis during endochondral bone formation in neonatal mice. J Bone Miner Res 2002;17:998.
Landesberg R, Cozin M, Cremers S, et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 2008;66:839–47.
Katz J, Gong Y, Salmasinia D, et al. Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw. Int J Oral Maxillofac Surg 2011;40:605–11.
Nicoletti P, Cartsos V, Palaska P, et al. Genomewide pharmocogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3. Int J Oral Maxillofac Surg 2012;17:1–9.
Sarasquete M. BRONJ is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide analysis. Blood 2008;111:2709.
Marx R, Sawatari Y, Fortin M. Bisphosphonateinduced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg 2005;63:1567–75.
Ruggiero S, Fantasia J, Carlson E. Bisphosphonaterelated osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102:433–41.
Ruggiero S, Mehrotra B, Rosenberg T. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34.
Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons. Position paper on bisphosphonate-related osteonecrosis of the jaw. J Oral Maxillofac Surg 2007;65(3):369–76.
Ruggiero S, Dodson T, Assael L, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws: 2009 update. J Oral Maxillofac Surg 2009;67:2–12.
Treister N, Friedland B, Woo S. Use of cone-beam computerized tomography for evaluation of bisphosphonate-associated osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;109:753–64.
Arce K, Assael L, Weissman J, et al. Image findings in bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2009;67(Suppl 1):75–84.
Greenspan SI, Rosen HN, Parker RA: Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women, J Clin Endocrinol Metab 85:3537-3540, 2000.
Marx RE: Oral and intravenous bisphosphonate-induced osteonecrosis of the jaws: history, etiology, prevention, and treatment, Chicago, 2007, Quintessence.
Otto S, Troltzsch M, Jambrovic V: Tooth extraction in patients receiving oral and intravenous bisphosphonate administration: A trigger for BRONJ development? Journal of Cranio-Maxillo-Facial Surgery 43 (2015) 847-854.
